Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

Completed · Phase 1

Conditions studied: Healthy

In brief

Researchers have designed a study medicine called bomedemstat (MK-3543) as a new way to treat certain rare blood diseases. The purpose of this study is to learn what happens to bomedemstat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to bomedemstat in the body when it is given alone and after multiple doses of another medicine called carbamazepine (CBZ).

Key facts

Study ID: NCT06596668
Run by: Merck Sharp & Dohme LLC
People needed: 16
Starts: 2024-10-02
Expected to finish: 2025-03-11
Last updated by the study team: 2025-03-18

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

The main inclusion criteria include but are not limited to the following:
Non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months before entering the study.
Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2
Medically healthy with no clinically significant medical history

You may not qualify if…

The main exclusion criteria include but are not limited to the following:
History or presence of any of the following:
Seizures
Negative reactions in the blood system to any drugs
Depression, unusual changes in mood or behavior or suicidal thoughts or behavior
History of cancer
Regular user of cannabis products within 6 months before entering the study.
Unable to stop using or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days before entering the study.

Where it is running

Celerion, Inc. ( Site 0001) — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.